Revolution Medicines (United States)
company in Redwood City, United States
RVMD Nasdaq
ISIN US76155X1000 SEC CIK 1628171 LEI 549300JU3X0LBCQ65892
Follow Revolution Medicines (United States)
Weekly email: filings, results
Revenue, last quarter
$197.6M
Net income
−$407.5M
−33.5% vs same quarter last year
EPS, diluted
−$1.90
−18% vs same quarter last year
Operating cash flow
−$415.7M
−100.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$1.1B |
| FY24 | $0 | −$600M |
| FY23 | $11.6M | −$436M |
| FY22 | $35.4M | −$249M |
| FY21 | $29.4M | −$187M |
| FY20 | $43M | −$108.2M |
| FY19 | $50M | −$47.7M |
| FY18 | $20.2M | −$41.8M |
| FY17 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | −4207.1% | −3765.1% |
| FY22 | −730% | −703.8% |
| FY21 | −639.7% | −636.3% |
| FY20 | −257.5% | −251.6% |
| FY19 | −108.2% | −95.2% |
| FY18 | −200% | −207.2% |
| FY17 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$913.7M |
| FY24 | −$567.7M |
| FY23 | −$358.3M |
| FY22 | −$235.2M |
| FY21 | −$153.7M |
| FY20 | −$103M |
| FY19 | −$52.2M |
| FY18 | −$286K |
| FY17 | - |
- Revolution Medicines (United States)
- Healthcare median
Show the numbers
| Year | Revolution Medicines (United States) | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | −3765.1% | −58% |
| FY22 | −703.8% | −80.4% |
| FY21 | −636.3% | −71.9% |
| FY20 | −251.6% | −62.2% |
| FY19 | −95.2% | −46.3% |
| FY18 | −207.2% | −49.6% |
| FY17 | - | −45.9% |